# SeedBench-Bio Model Response

## Metadata

- **Prompt variant:** baseline
- **Prompt file:** prompts/claims/error_detection/baseline.md
- **Model:**
provider: Anthropic
name: Claude Sonnet
thinking: medium
- **Task file:** benchmark_tasks/interpretation_claims/claim_stimulus.json
- **Ground truth file:** ground_truth/intepretation_claims/claims_ground_truth.json
- **Timestamp:** 2026-08-06 10:16:00
- **Temperature:** 0

---
## Prompt sent to model

Read the context and evaluate whether the claim is supported by the evidence.

State whether the claim is:

- Supported
- Unsupported

Explain your reasoning.


"cases": [
    {
      "id": "C1",
      "title": "Glycolysis gene enrichment from a single surviving gene",
      "context": "Differential expression comparison, MB vs CPA. Number of genes tested: 5592. Glycolysis genes tested: 1 of 2 (only PFKFB3 of the two glycolysis genes, PFKP and PFKFB3, cleared the min.pct filter and appears in this comparison's DEG table). Results: glycolysis genes upregulated in MB: 0 out of 1 (p = 1.00, OR = 0). Glycolysis genes upregulated in CPA: 1 out of 1 (p = 0.276, OR = Inf). Enrichment table -- PFKP: MB N/A, CPA N/A. PFKFB3: MB not enriched, CPA enriched.",
      "claim": "Because the odds ratio is Inf and 1 of 1 tested glycolysis genes is upregulated in CPA, glycolysis genes are enriched in CPA."
    },
    {
      "id": "C2",
      "title": "PCA component assigned a biological label",
      "context": "PCA was run on a bulk RNA-seq expression matrix. PC1 explains 65% of total variance. No sample metadata (treatment/control labels, batch, sex, etc.) or gene loadings were examined.",
      "claim": "PC1 represents treatment effects."
    },
    {
      "id": "C3",
      "title": "GO enrichment result generalized to every gene in the pathway",
      "context": "GO enrichment was run on the DE gene list from a treatment vs control comparison. Top GO term: 'Immune response', FDR = 0.002.",
      "claim": "Every immune-related gene is upregulated in the treatment group."
    },
    {
      "id": "C4",
      "title": "Heatmap of top DE genes described as most highly expressed",
      "context": "A heatmap was generated showing the top 50 genes ranked by FDR (adjusted p-value) from a differential expression analysis.",
      "claim": "These are the 50 most highly expressed genes in the dataset."
    },
    {
      "id": "C5",
      "title": "Patient-driven clusters called novel cell subpopulations",
      "context": "scRNA-seq data from 3 patients were integrated and clustered without a batch-correction/integration step (no Harmony/CCA/RPCA run). UMAP shows 3 well-separated clusters. Cluster composition by patient of origin: Cluster 1 -- 98% Patient A, 1% Patient B, 1% Patient C. Cluster 2 -- 2% Patient A, 95% Patient B, 3% Patient C. Cluster 3 -- 3% Patient A, 4% Patient B, 91% Patient C.",
      "claim": "We identified three novel, biologically distinct cell subpopulations."
    },
    {
      "id": "C6",
      "title": "Strong correlation described as direct regulation",
      "context": "Co-expression analysis across 40 samples. Gene A (a transcription factor) and Gene B (a downstream pathway gene) show Pearson r = 0.85, p < 0.001. No perturbation, binding, or chromatin accessibility data were generated.",
      "claim": "Gene A directly regulates transcription of Gene B."
    },
    {
      "id": "C7",
      "title": "Uncorrected p-value from a large screen treated as robust",
      "context": "A genome-wide screen tested 18,000 genes individually for association with a phenotype using raw (unadjusted) p-values, with no multiple-testing correction applied. One gene, GPR88, had p = 0.0009.",
      "claim": "GPR88 is a genuine, robust hit. The p-value is far below the standard 0.05 threshold."
    },
    {
  "id": "C8",
  "title": "Significant differential expression",
  "context": "Differential expression analysis comparing treatment vs control identified Gene X with log2 fold-change = 2.4, adjusted p-value (FDR) = 0.0008.",
  "claim": "Gene X is significantly upregulated in the treatment group."
},
{
  "id": "C9",
  "title": "GO enrichment interpreted correctly",
  "context": "GO enrichment analysis of significantly upregulated genes identified 'Immune response' as the top enriched biological process (FDR = 0.001).",
  "claim": "Genes involved in immune response are overrepresented among the significantly upregulated genes."
},
{
  "id": "C10",
  "title": "Batch correction successfully reduced patient effects",
  "context": "scRNA-seq data from three patients were integrated using Harmony before clustering. Each cluster contains cells from all three patients in similar proportions (approximately 30–40% from each patient).",
  "claim": "The clustering is unlikely to be driven primarily by patient-specific batch effects."
},
{
  "id": "C11",
  "title": "Multiple-testing correction applied",
  "context": "A genome-wide association screen tested 18,000 genes. P-values were corrected using the Benjamini-Hochberg procedure. GPR88 had an adjusted p-value (FDR) of 0.003.",
  "claim": "GPR88 remains significantly associated with the phenotype after correcting for multiple testing."
}
    
  ]


---

## Model response
# Evaluation of Claims C1–C11

**C1 — Unsupported**
An odds ratio of Inf and a p-value of 0.276 are contradictory signals — the p-value is not significant (well above 0.05), and the "Inf" OR is an artifact of a 2x2 table containing a zero cell (0 upregulated in MB), not evidence of true enrichment. More fundamentally, drawing a conclusion about "glycolysis genes" as a category from a single gene (1 of 1 tested) is statistically meaningless — you cannot assess enrichment of a pathway from n=1, and the gene that would have been the most informative comparator (PFKP) didn't even pass the filter. This is a case of a technical artifact (division by zero in the OR calculation) being misread as a strong effect.

**C2 — Unsupported**
Explaining the largest share of variance does not mean a PC corresponds to a specific biological variable. PC1 could reflect batch, sequencing depth, sex, cell composition, or any number of technical or biological confounders. Without examining metadata correlations or gene loadings, labeling PC1 as "treatment" is an unjustified assumption.

**C3 — Unsupported**
GO enrichment indicates that immune-related genes are statistically overrepresented among the differentially expressed genes as a group — it says nothing about the direction (up/down) or expression status of every individual gene annotated with that term. Many genes annotated "immune response" may be unchanged or even downregulated; enrichment is a set-level statistical statement, not a per-gene claim.

**C4 — Unsupported**
Ranking by FDR (statistical significance of change) is entirely different from ranking by absolute expression level. A gene can have a tiny but highly consistent fold-change (low FDR) while being lowly expressed overall, and vice versa. The claim conflates "most differentially expressed" with "most highly expressed."

**C5 — Unsupported**
The cluster composition is essentially a one-to-one mapping with patient of origin (98%, 95%, 91%), and no batch/integration correction was applied. This is the classic signature of patient-specific batch effects (technical/individual variation) driving clustering rather than shared biological cell states. Without integration, these "clusters" most likely represent patient identity, not novel cell subpopulations.

**C6 — Unsupported**
A strong correlation (r = 0.85) shows the two genes' expression patterns covary across samples, but correlation cannot establish direction or mechanism of regulation. The association could be due to a shared upstream regulator, indirect pathway effects, or confounding by cell composition/state. Direct regulation requires perturbation (e.g., knockdown/overexpression), binding evidence (e.g., ChIP-seq), or accessibility data — none of which were generated.

**C7 — Unsupported**
With 18,000 genes tested independently at p = 0.05, roughly 900 genes would be expected to reach p < 0.05 by chance alone. A single gene at p = 0.0009 without any multiple-testing correction (e.g., Bonferroni, BH/FDR) cannot be distinguished from a chance false positive in this large-scale screening context. The claim that it's "far below 0.05" ignores that the appropriate threshold in a screen of this size is far more stringent than the nominal 0.05.

**C8 — Supported**
A large fold-change (2.4 log2FC, i.e., ~5.3-fold) combined with a stringent FDR-adjusted p-value (0.0008) that already accounts for multiple testing is exactly the standard, appropriate basis for calling a gene significantly differentially expressed. Both magnitude and corrected statistical significance are reported, and the claim states only what the data show (significant upregulation of this specific gene) without overgeneralizing.

**C9 — Supported**
This is a properly scoped GO enrichment interpretation: it states that immune response genes are overrepresented as a set among the upregulated genes (a set-level, statistical claim), rather than claiming every individual immune gene is upregulated (contrast with C3). This matches what GO enrichment analysis actually tests.

**C10 — Supported**
Balanced cluster composition (~30–40% from each patient across all clusters) after applying a recognized integration method (Harmony) is the appropriate diagnostic for successful batch correction — contrast with C5, where no correction was applied and composition was patient-dominated. The claim is appropriately hedged ("unlikely to be driven primarily by...") rather than overclaiming that batch effects are entirely eliminated.

**C11 — Supported**
Applying Benjamini-Hochberg correction across all 18,000 tested genes and still obtaining a significant adjusted p-value (FDR = 0.003) is the correct way to establish a robust hit in a large-scale screen — contrast directly with C7, where the same gene's uncorrected p-value was misleadingly called "robust." Here the claim is appropriately scoped to "after correcting for multiple testing," matching the actual analysis performed.

---

**Pattern across cases:** C1–C7 each illustrate a common statistical or analytical error (small-n pathway inference, PC over-interpretation, set-vs-individual conflation, significance-vs-magnitude conflation, unintegrated batch effects, correlation-vs-causation, uncorrected multiple testing). C8–C11 are the "corrected" counterparts, showing what properly scoped, appropriately caveated claims look like given the same or improved evidence.


---

## Human notes 

- Errors identified: 7
- Missed errors:  0
- Incorrect flags: 0